$18.22
+0.27
(+1.5%)▲
Live
0.49%
Downside
Day's Volatility :1.52%
Upside
1.03%
55.79%
Downside
52 Weeks Volatility :57.78%
Upside
4.51%
Period | Teva Pharmaceutical Industries Ltd | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 5.71% | 3.6% | 0.0% |
6 Months | 39.36% | 10.2% | 0.0% |
1 Year | 119.44% | 19.6% | 0.0% |
3 Years | 77.02% | 16.8% | -23.0% |
Market Capitalization | 20.3B |
Book Value | $5.61 |
Earnings Per Share (EPS) | -0.39 |
PEG Ratio | 1.29 |
Wall Street Target Price | 21.14 |
Profit Margin | -2.78% |
Operating Margin TTM | 19.62% |
Return On Assets TTM | 5.16% |
Return On Equity TTM | -10.51% |
Revenue TTM | 16.3B |
Revenue Per Share TTM | 14.49 |
Quarterly Revenue Growth YOY | 7.3999999999999995% |
Gross Profit TTM | 7.0B |
EBITDA | 4.6B |
Diluted Eps TTM | -0.39 |
Quarterly Earnings Growth YOY | 0.4 |
EPS Estimate Current Year | 2.45 |
EPS Estimate Next Year | 2.76 |
EPS Estimate Current Quarter | 0.55 |
EPS Estimate Next Quarter | 0.65 |
What analysts predicted
Upside of 16.03%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 18.9B | ↓ 15.77% |
Net Income | -2.2B | ↓ 86.78% |
Net Profit Margin | -11.4% | ↑ 61.26% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 16.9B | ↓ 10.43% |
Net Income | -999.0M | ↓ 53.53% |
Net Profit Margin | -5.92% | ↑ 5.48% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 16.7B | ↓ 1.36% |
Net Income | -4.0B | ↑ 299.4% |
Net Profit Margin | -23.95% | ↓ 18.03% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 15.9B | ↓ 4.68% |
Net Income | 417.0M | ↓ 110.45% |
Net Profit Margin | 2.63% | ↑ 26.58% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 14.9B | ↓ 6.0% |
Net Income | -2.4B | ↓ 664.27% |
Net Profit Margin | -15.77% | ↓ 18.4% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 15.8B | ↑ 6.17% |
Net Income | -559.0M | ↓ 76.24% |
Net Profit Margin | -3.53% | ↑ 12.24% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.7B | ↓ 5.74% |
Net Income | -205.0M | ↓ 83.21% |
Net Profit Margin | -5.6% | ↑ 25.84% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.9B | ↑ 5.93% |
Net Income | -863.0M | ↑ 320.98% |
Net Profit Margin | -22.25% | ↓ 16.65% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.9B | ↓ 0.72% |
Net Income | 80.0M | ↓ 109.27% |
Net Profit Margin | 2.08% | ↑ 24.33% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.5B | ↑ 15.77% |
Net Income | 429.0M | ↑ 436.25% |
Net Profit Margin | 9.63% | ↑ 7.55% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 3.8B | ↓ 14.02% |
Net Income | -139.0M | ↓ 132.4% |
Net Profit Margin | -3.63% | ↓ 13.26% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 4.2B | ↑ 8.61% |
Net Income | -845.0M | ↑ 507.91% |
Net Profit Margin | -20.3% | ↓ 16.67% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 60.7B | ↓ 14.07% |
Total Liabilities | 44.9B | ↓ 13.46% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 57.5B | ↓ 5.29% |
Total Liabilities | 42.4B | ↓ 5.53% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 50.6B | ↓ 11.88% |
Total Liabilities | 39.6B | ↓ 6.67% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 47.7B | ↓ 5.87% |
Total Liabilities | 36.4B | ↓ 7.98% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 44.0B | ↓ 7.68% |
Total Liabilities | 35.3B | ↓ 3.04% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 43.5B | ↓ 1.2% |
Total Liabilities | 35.4B | ↑ 0.11% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 43.5B | ↓ 1.25% |
Total Liabilities | 34.8B | ↓ 1.33% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 43.1B | ↓ 0.83% |
Total Liabilities | 35.4B | ↑ 1.56% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 42.1B | ↓ 2.34% |
Total Liabilities | 34.6B | ↓ 2.29% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 43.5B | ↑ 3.3% |
Total Liabilities | 35.4B | ↑ 2.24% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 42.8B | ↓ 1.62% |
Total Liabilities | 35.2B | ↓ 0.35% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 41.3B | ↓ 3.35% |
Total Liabilities | 34.8B | ↓ 1.29% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.4B | ↓ 30.25% |
Investing Cash Flow | 1.9B | ↓ 13.77% |
Financing Cash Flow | -3.4B | ↓ 41.72% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 538.0M | ↓ 78.0% |
Investing Cash Flow | 1.4B | ↓ 27.38% |
Financing Cash Flow | -241.0M | ↓ 92.81% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.2B | ↑ 126.02% |
Investing Cash Flow | 863.0M | ↓ 36.31% |
Financing Cash Flow | -1.9B | ↑ 682.16% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 798.0M | ↓ 34.37% |
Investing Cash Flow | 1.5B | ↑ 76.48% |
Financing Cash Flow | -2.2B | ↑ 15.23% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.6B | ↑ 99.25% |
Investing Cash Flow | 656.0M | ↓ 56.93% |
Financing Cash Flow | -1.5B | ↓ 31.54% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -145.0M | ↓ 114.9% |
Investing Cash Flow | 302.0M | ↑ 79.76% |
Financing Cash Flow | -706.0M | ↓ 0.98% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 324.0M | ↓ 323.45% |
Investing Cash Flow | 302.0M | ↑ 0.0% |
Financing Cash Flow | -55.0M | ↓ 92.21% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 5.0M | ↓ 98.46% |
Investing Cash Flow | 184.0M | ↓ 39.07% |
Financing Cash Flow | -576.0M | ↑ 947.27% |
Sell
Neutral
Buy
Teva Pharmaceutical Industries Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Teva Pharmaceutical Industries Ltd | 1.3% | 39.36% | 119.44% | 77.02% | 120.25% |
Neurocrine Biosciences Inc. | 0.22% | -11.71% | 9.36% | 13.47% | 21.32% |
Haleon Plc Spon Ads | -5.08% | 20.69% | 22.01% | 36.17% | 36.17% |
Zoetis Inc. | -0.16% | 32.8% | 16.08% | -7.35% | 52.85% |
Viatris Inc. | 2.53% | 4.53% | 31.84% | -16.06% | -28.03% |
Catalent, Inc. | 0.9% | 7.56% | 42.8% | -54.43% | 23.98% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Teva Pharmaceutical Industries Ltd | 30.17 | NA | 1.29 | 2.45 | -0.11 | 0.05 | NA | 5.61 |
Neurocrine Biosciences Inc. | 35.55 | 35.55 | 0.27 | 4.54 | 0.16 | 0.12 | NA | 24.87 |
Haleon Plc Spon Ads | 32.52 | 32.52 | 1.5 | 0.39 | 0.07 | 0.04 | 0.02 | 1.82 |
Zoetis Inc. | 37.9 | 37.9 | 2.64 | 5.83 | 0.49 | 0.14 | 0.01 | 10.94 |
Viatris Inc. | 224.4 | NA | 0.07 | 2.67 | -0.03 | 0.03 | 0.04 | 16.36 |
Catalent, Inc. | 211.02 | NA | 3.02 | 0.2 | -0.25 | 0.0 | NA | 19.91 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Teva Pharmaceutical Industries Ltd | Sell | $20.3B | 120.25% | 30.17 | -2.78% |
Neurocrine Biosciences Inc. | Buy | $11.9B | 21.32% | 35.55 | 16.0% |
Haleon Plc Spon Ads | Buy | $45.6B | 36.17% | 32.52 | 9.66% |
Zoetis Inc. | Buy | $87.6B | 52.85% | 37.9 | 26.29% |
Viatris Inc. | Hold | $14.0B | -28.03% | 224.4 | -4.24% |
Catalent, Inc. | Hold | $10.9B | 23.98% | 211.02 | -23.81% |
Insights on Teva Pharmaceutical Industries Ltd
Revenue is up for the last 2 quarters, 3.83B → 4.16B (in $), with an average increase of 7.9% per quarter
Netprofit is down for the last 3 quarters, 429.0M → -845.0M (in $), with an average decrease of 320.2% per quarter
BlackRock Inc
FMR Inc
Ion Asset Management Ltd.
Clal Insurance Enterprises Holdings Ltd
Migdal Insurance & Financial Holdings Ltd
MENORA MIVTACHIM HOLDINGS LIMITED
In the quarter ending June,2017. Teva Pharmaceutical Industries Ltd has declared dividend of $0.09
Read MoreTeva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.
Organization | Teva Pharmaceutical Industries Ltd |
Employees | 35001 |
CEO | Mr. Richard D. Francis |
Industry | Health Technology |